Question

Alkylating chemotherapy agents are particularly effective against blood cancers. Because of this though, individuals may be at risk for what condition?

a) Anemia
b) Hypertension
c) Osteoporosis
d) Neurological disorders

Answer 1

Individuals undergoing alkylating chemotherapy treatment for blood cancers are at risk of developing aplastic anemia due to the bone marrow's reduced ability to produce new blood cells. A neutrophil count within the acceptable range suggests that chemotherapy can safely continue.

Step-by-step explanation:

Alkylating chemotherapy agents, often used to treat blood cancers, can cause collateral damage to the body's normal cells, including those in the bone marrow. One of the known side effects is the risk of developing aplastic anemia, a condition where the bone marrow does not produce sufficient new cells to replenish blood cells. The bone marrow's function is critical in producing red blood cells, white blood cells, and platelets. Consequently, chemotherapy can impair its ability to generate these vital components, leading to aplastic anemia.

The destruction of leukocytes, such as neutrophils, by chemotherapy is a particular concern. A neutrophil count of 1900 cells per microliter, as mentioned, is within the acceptable range (>1500 cells/µL), indicating that a patient's immune function may still be adequate for chemotherapy to proceed.